Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin.

ABSTRACT: Urothelial carcinoma is a common malignancy that affects the urinary system, with bladder cancer being the most prevalent form. Although the management of early-stage disease has seen significant improvements, the treatment of locally advanced and metastatic urothelial carcinoma remains challenging. Over the past decade, there has been an explosion in the number of therapies available for the treatment of advanced disease, with immune checkpoint inhibitors and antibody-drug conjugates leading the way. Enfortumab vedotin is an antibody-drug conjugate that targets Nectin-4, a protein that is overexpressed in urothelial carcinoma cells. In clinical trials, it has shown promising outcomes for the treatment of advanced urothelial carcinoma that has progressed after chemotherapy or immunotherapy

SUBMITTER: Shafique MA 

PROVIDER: S-EPMC10362867 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature